Literature DB >> 33868661

An Uncommon Cause of Hematemesis.

Madeline Bertha1, Lisa B VanWagner1,2.   

Abstract

Year:  2021        PMID： 33868661      PMCID： PMC8043707          DOI： 10.1002/cld.1015

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  10 in total

Review 1.  Approach to the diagnosis of portal hypertension.

Authors:  Christopher Koh; Theo Heller
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-11-09

2.  Incidence of portal hypertension in patients exposed to oxaliplatin.

Authors:  Stefania Gioia; Michele Di Martino; Marina Minozzi; Silvia Nardelli; Enrico Cortesi; Oliviero Riggio
Journal:  Dig Liver Dis       Date:  2019-07-15       Impact factor: 4.088

3.  Noncirrhotic portal hypertension: An overview.

Authors:  Ohad Etzion; Christopher Koh; Theo Heller
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-09-29

4.  Severe sinusoidal lesions: a serious and overlooked complication of oxaliplatin-containing chemotherapy?

Authors:  Ramuntxo Arotçarena; Valérie Calès; Philippe Berthelémy; Yves Parent; Maxime Malet; Francine Etcharry; Sylvie Ferrari; Alexandre Pariente
Journal:  Gastroenterol Clin Biol       Date:  2006-11

5.  Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.

Authors:  Michael J Overman; Dipen M Maru; Chusilp Charnsangavej; Evelyn M Loyer; Huamin Wang; Priyanka Pathak; Cathy Eng; Paulo M Hoff; Jean-Nicolas Vauthey; Robert A Wolff; Scott Kopetz
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

6.  Porto-sinusoidal vascular disease: proposal and description of a novel entity.

Authors:  Andrea De Gottardi; Pierre-Emmanuel Rautou; Jeoffrey Schouten; Laura Rubbia-Brandt; Frank Leebeek; Jonel Trebicka; Sarwa Darwish Murad; Valérie Vilgrain; Virginia Hernandez-Gea; Filipe Nery; Aurélie Plessier; Annalisa Berzigotti; Paulette Bioulac-Sage; Massimo Primignani; David Semela; Laure Elkrief; Pierre Bedossa; Dominique Valla; Juan Carlos Garcia-Pagan
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-05

7.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Authors:  L Rubbia-Brandt; V Audard; P Sartoretti; A D Roth; C Brezault; M Le Charpentier; B Dousset; P Morel; O Soubrane; S Chaussade; G Mentha; B Terris
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

9.  The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Authors:  Michael J Overman; Renata Ferrarotto; Kanwal Raghav; Binsah George; Wei Qiao; Karime K Machado; Leonard B Saltz; Thibault Mazard; J N Vauthey; Paulo M Hoff; Brian Hobbs; Evelyn M Loyer; Scott Kopetz
Journal:  J Natl Cancer Inst       Date:  2018-08-01       Impact factor: 13.506

Review 10.  Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It.

Authors:  Angela Puente; Jose Ignacio Fortea; Carmen Del Pozo; Patricia Huelin; Maria Luisa Cagigal; Marina Serrano; Joaquin Cabezas; Maria Teresa Arias Loste; Paula Iruzubieta; Antonio Cuadrado; Susana Llerena; Carlos Lopez; Emilio Fábrega; Javier Crespo
Journal:  Cells       Date:  2019-11-24       Impact factor: 6.600
  10 in total
  1 in total

Review 1.  Interventional Management of Portal Hypertension in Cancer Patients.

Authors:  Max Kabolowsky; Lyndsey Nguyen; Brett E Fortune; Ernesto Santos; Sirish Kishore; Juan C Camacho
Journal:  Curr Oncol Rep       Date:  2022-08-12       Impact factor: 5.945
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.